Breast Cancer
Conditions
Keywords
neoadjuvant chemotherapy, Abraxane, Xeloda
Brief summary
Some studies have demonstrated the efficacy of Abraxane in treating breast cancer in both adjuvant and metastatic settings. Few data is available on Abraxane in neoadjuvant treatment for breast cancer. The aim of this project is to evaluate tailored primary systemic therapy with weekly Abraxane (125mg/m2) Combined With Q3week Xeloda (1250mg/m2) in early operable (stage of T2-4N0-3M0) breast cancer. This study will be an open label non randomized, single arm, single center study.
Detailed description
The hypothesis is that tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is feasible and achieves high response rates. It is proposed that 50 patients will be enrolled in this study. The target population is women with early breast cancer (stage of T2-4N0-3M0) who are eligible for primary systemic therapy. The primary objective of the trial is to determine the overall response rate. Secondary endpoints will include response rates in axillary lymph nodes, safety and tolerability and the rate of breast conservation.
Interventions
DRUGAbraxane
Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
DRUGXeloda
Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
Sponsors
Zhejiang Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
1. Provision of informed consent 2. Women and men at least 18 years of age or older. 3. Pathological confirmation of breast cancer 4. Tumor stage(TNM):T2-4N0-3M0 5. No evidence of distant metastasis 6. Adequate bone marrow, hepatic, and renal function 7. Measurable disease as per RECIST criteria 8. Karnofsky≥70 9. Laboratory criteria: PLT≥100\*109/L WBC≥4000/mm3 HGB≥10g/dl ALT and AST\<2\*ULN
Exclusion criteria
1. Presence of metastatic disease. 2. Inflammatory breast cancer. 3. Bilateral breast cancer. 4. previous chemotherapy or hormonal therapy for current breast neoplasm. 5. other malignant tumors (concurrent or previous). 6. Pregnant woman. 7. Hypersensitive to any drug in Abraxane or Xeloda regimen or any ingredient of Abraxane or Xeloda. 8. Any severe systemic disease contraindicating chemotherapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR(CR+PR) | Following the completion of 12 weeks of neoadjuvant chemotherapy Treatment | To evaluate the efficacy of concurrent Abraxane and Xeloda as neoadjuvant regimen in terms of: ORR(CR+PR), downstaging rates in tumor size and axillary lymph node. Pathological Complete Response(pCR) defined by: defined as ypT0, ypN0 (the absence of residual invasive and in situ cancer on evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Side Effects. | First Dose of Abraxane and Xeloda up to 24 months | Determine side effects of these drugs like cardiotoxicity ,hematological toxicity，gastrointestinal symptoms and so on. |
| Event Free Survival(DFS) | Time of Surgery up to 5 years | Time of surgery to first documentation of local or distant recurrence, or death or initiation of antineoplastic therapy before documentation of first relapse. |
| Overall Survival(OS) | First Dose of Abraxane and Xeloda up to 5 years | Time from the first dose of Abraxane and Xeloda to death due to any cause |
Contacts
Primary ContactDing Xiaowen, Doc
Backup ContactDing Yuqin
Outcome results
None listed